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Mastitis is one of the most costly diseases to the dairy cow industry. Implementation 
of management protocols have decreased the incidence rate of contagious mastitis 
pathogens, while the incidence of cases caused by environmental pathogens, such as 
Escherichia coli (E. coli) and Streptococcus uberis (Strep. uberis), remains 
unchanged. Currently, antibiotics are the primary therapy utilized to control mastitis. 
However, growing concern for antibiotic overuse, improper use and bacterial 
resistance have led to the examination of alternative strategies. Two promising 
alternative mitigation strategies were explored in the research leading to this 
dissertation. The first is a potent endolysin, PlyC, which has demonstrated 
bactericidal activity against several streptococcal species in a variety of applications. 
However, it is unknown how PlyC interacts with the bovine immune system. Varying 
doses of PlyC were non-toxic and did not alter the oxidative burst response of bovine 
neutrophils, the first immune cells recruited to the intramammary infection. The 
  
second alternative to an antimicrobial drug explored was citrus oil dissolved in 
ethanol. This was tested against E. coli strain P4. Prior antimicrobial investigations 
with citrus oil utilized dimethylsulfoxide as a carrier solvent, which is currently 
prohibited in the dairy industry. Citrus oil and its primary components were tested to 
determine minimum inhibitory, bactericidal and biofilm eradication concentrations. 
Citrus oil components, citral and linalool, demonstrated better antimicrobial activity 
than the native oil in vitro. In addition, citral and linalool were minimally toxic to 
bovine neutrophils and did not hinder their oxidative burst response in vitro. Because 
citral demonstrated greater antimicrobial activity than linalool, it was the logical 
candidate to test for the efficacy as an intramammary therapy against experimentally-
induced E. coli mastitis. Unfortunately, citral treatment did not differ from a common 
intramammary antibiotic therapy or sterile buffered solution. In conclusion, the use of 
PlyC as an alternative therapy for Strep. uberis mastitis is promising as PlyC may not 
interfere with immune response during mastitis. The antimicrobial effects of citral 
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Chapter 1: Introduction and Literature Review 
 
Introduction 
Bovine mastitis, an inflammation of the mammary gland, is the most costly 
disease impacting the dairy industry. Numerous pathogens are responsible for mastitis 
with the majority of infections caused by staphylococci, streptococci and coliforms. 
These pathogens are typically grouped by their transmission method into two groups: 
contagious and environmental. Current management practices have successfully 
decreased the prevalence of cases caused by contagious bacteria, but incidence rates 
caused by environmental bacteria remain steady. Due to the predominance of 
infectious mastitis and the importance of the use of antimicrobial agents in the 
treatment and control of it, this microbial infection continues to be a subject of 
investigation by several groups. However, there is a significant information gap 
concerning novel research into controlling environmental mastitis through nondrug 
strategies (i.e., alternatives to antimicrobial drugs). 
Currently, antibiotic therapy is the main strategy for mastitis treatment and 
control. Detection of clinical mastitis is typically based on the observation of 
manifestations of inflammation. The majority of producers treat mastitis on these 
symptoms and not etiology. Antibiotic use has the potential to create drug residues in 
milk and meat for human consumption and presents a concern for consumers. Cost of 
use, emergence of antibiotic resistance, and governmental regulatory legislative 





necessitated and created opportunities for the search for, development and 
implementation of alternative strategies and therapies to manage mastitis and 
minimize antibiotic use in food-producing animals without the use of antibiotic drugs.  
Several antimicrobial alternatives have recently been explored and two 
promising ones were investigated in this work. Recombinantly-derived endolysin 
PlyC is one of the most potent lysins to date as nanograms can eliminate billions of 
species-specific bacteria in seconds. In contrast, citrus oil and specifically its active 
components, have demonstrated many uses in the food industry as flavor compounds, 
anti-oxidants and preservatives. In human and animal health, the essential oils have 
useful antimicrobial activities, including anti-biofilm activity, inhibition of growth 
and the eradication of many bacterial and fungal species, and anti-inflammatory 
effects. Vastly different in origin and activity, both PlyC and citrus oil may be useful 
therapies and alternative to antibiotic treatment for bovine mastitis.  
The chapters in this dissertation explore the possible use of PlyC and citrus oil 
as antimicrobial therapies for bovine mastitis. 
 
Mastitis 
Commonly defined as inflammation of the mammary gland, mastitis is the 
most prevalent and economically significant disease in the bovine dairy industry (US 
Department of Agriculture, 2009). The estimated losses to producers in the United 
States exceed $2 billion per year with each clinical case costing approximately $179 
(Cha et al., 2011), and the majority of financial losses can be attributed to reduced 





Additional costs are attributed to reduced milk quality, loss of milk quality premiums, 
treatment costs, veterinary care, increased labor costs, increased risk of removal from 
the herd, and discarded milk from antibiotic-treated cows during the Food and Drug 
Administration (FDA) mandated withdrawal period following antibiotic cessation. 
Since mastitis reduces the earning potential of affected cows and profitability of dairy 
operations, farmers seek to prevent, manage, diagnose and treat mastitis in their herd 
as effectively as possible.  
Mastitis cases are characterized by the severity of the inflammatory response 
of the animal. Clinical cases are observable, recognized and easily defined through 
the appearance of symptoms. The clinical syndrome can present as mild, moderate or 
severe based on the severity of these symptoms. In some instances, the case may 
become chronic and persist in a subclinical form with occasional clinical appearances. 
Although clinical cases are easily defined and treated in the dairy industry, it is the 
subclinical cases that are of greatest concern to producers as subclinical case 
prevalence can range from 5-75% (Erskine, 2016). As subclinical cases are not 
observable or easily defined, they require further testing to detect their presence. 
Typically, subclinical mastitis cases are diagnosed through decreased milk yield, 
altered milk composition, and increased milk somatic cell count (SCC) and bacterial 
count (Blowey and Edmondson, 2010). Because the cow appears healthy and her milk 
normal, managers often overlook the diagnosis and treatment of these cases.  
Regardless of presentation, diagnosis of mastitis is typically determined 
through observation of clinical symptoms and further testing of milk for composition 





detection is based upon visualization and palpation of the mammary glands to detect 
the presence of an inflammatory response presumably to the infection. In clinical 
mastitis, the udder may turn red in color, and feel hard and hot to the touch as 
vascularity and blood flow change in the inflamed gland (Erskine, 2016). In some 
cases, palpation of the udder may even be painful to the cow. Additional visual 
symptoms will include abnormal milk from the infected quarters of the mammary 
gland at time of milking. Milk may appear serous, abnormal in color, or contain 
flakes or clots. Most milk abnormalities are observed when a milking technician 
strips milk from each quarter at the beginning of the milking protocol. Following 
milking, technicians may also note that mastitic cows have decreased total milk yield 
(Gill et al., 1990). If clinical symptoms are not present, further testing of milk for 
mastitis diagnosis is typically completed off-farm. Milk samples from the bulk tank 
or suspected infected animals can be sent to state or privately-owned laboratories to 
determine if milk contains pathogens, high SCC concentrations or abnormal 
composition. Elevated SCC (i.e., greater than 200,000 cells/mL for composite 
foremilk samples; 100,000 cells/mL for quarter foremilk samples) or somatic cell 
score (SCS; i.e., greater than 4) from either a composite or an individual quarter 
samples is one of the most common factors used to confirm the presence of mastitis 
(Pighetti et al., 2007).  
Several factors contribute the nature of how mastitis is classified and therefore 
managed and treated. A wide variety of pathogens cause bovine mastitis including 
bacteria, yeast, viruses and algae. These pathogens may cause clinical or subclinical 





the infection and overall immune response from the animal (Wagner and Erskine, 
2009). Mastitis pathogens are generally categorized into either environmental or 
contagious categories, based upon the organism’s epidemiology. Historically, the 
most common contagious pathogens have been Staphylococcus aureus (Staph. 
aureus) and Streptococcus agalactiae (Strep. agalactiae); whereas, common 
environmental organisms include coagulase-negative Streptococcus species, 
Streptococcus uberis (Strep. uberis), Streptococcus dysgalactiae (Strep. 
dysgalactiae), Klebsiella species, and Escherichia coli (E. coli; Oliveira et al., 2013; 
Ruegg, 2015; National Mastitis Council, 2017). The adoption of modern milking 
practices, such as post-milking teat disinfection, dry cow therapy, milking and 
housing hygiene and culling chronic mastitic cows, have led to a notable decline in 
the prevalence of clinical mastitis caused by contagious pathogens (Blowey and 
Edmondson, 2010). However, the number of clinical cases caused by environmental 
pathogens remains relatively unchanged even with the addition of improved 
environmental hygiene, pre-dipping and use of teat sealants during the dry period 
(Bradley et al., 2007). 
 
Environmental Mastitis 
Environmental bacteria are an important cause of clinical mastitis on well-
managed dairies and are most often isolated from acute clinical cases of mastitis 
(Barkema et al., 1998; Olde Riekerink et al., 2008). Gram-negative bacteria are 
typically considered environmental mastitis pathogens (National Mastitis Council, 





bacteria. E. coli, Klebsiella and Enterobacter are coliforms; however, other Gram-
negative bacteria are also frequently isolated from intramammary infections (Serratia, 
Pseudomonas, and Proteus). Gram-negative bacteria occupy many habitats in the 
cow’s environment and may be isolated from virtually any surface are of the cow or 
her surroundings. Entry of Gram-negative bacteria into the mammary gland is 
through the teat canal, and rapidly adjust and multiply in the lactose-rich and 
anaerobic conditions. Populations of coliforms can reach peak concentrations 
exceeding 108 colony forming units (CFU) per mL of milk in clinical cases in hours 
(Hogan et al., 1992). In subclinical cases and infections in later phases, concentrations 
are typically 102 CFU/mL milk. Low shedding rates and environmental pathogens 
contributing to the majority of sample contamination can make it difficult to diagnose 
intramammary infections caused by Gram-negative, environmental bacteria (Hogan 
and Smith, 2003). 
Streptococcal (Gram-positive) species also originate in the environment and 
are responsible for high incidences of environmental mastitis. The majority of 
streptococcal infections originate during the dry and transition periods with Strep. 
uberis as the primary pathogen (Jayarao et al., 1999). Strep. uberis is one of the most 
common causes of clinical and subclinical mastitis in the United Kingdom and New 
Zealand (Zadoks, 2007; Petrovski et al., 2011). A ubiquitous microorganism, Strep. 
uberis has been localized on the cow and inside the cow, as well as the environment 
(Zadoks, 2007). Straw and other organic bedding material enhance the growth of 
Strep. uberis and increase the likelihood of intramammary infections (Blowey and 





through the teat canal, however species like Strep. uberis can take longer to adjust 
and establish infections as compared to Gram-negative bacteria. Strep. uberis 
infections initiate the immune response within a d of post infection and peak CFU 
concentrations in milk 104 CFU/mL occur 5-6 d post infection (Pedersen et al., 2003; 
Rambeaud et al., 2003). 
Clinical mastitis in most dairy herds is caused by environmental pathogens 
(Gruet et al., 2001). These cases, especially initial episodes, are typically transient; 
therefore, the epidemiology of clinical mastitis is typically assessed on incidence rate 
(the number of new cases per population at risk in a given time period) and not 
prevalence (the proportion of a population affected; Rothman et al., 2008). The 
methods for monitoring and diagnosing mastitis in individual cows are poor 
predictors of herd clinical mastitis episodes. Cows with chronic infections and 
increased SCC may occasionally display clinical mastitis. Cows with low SCC are 
also prone to developing clinical mastitis and may have a higher incidence rate of 
clinical cases caused by environmental organisms (30-50 cases/100 cows/year; Paape 
et al., 2002) than herds of cows with higher SCC. An inverse relationship exists 
between incidence and severity of clinical mastitis caused by Gram-negative bacteria, 
and milk SCC (Barkema et al., 1998).  Incidence rate and probable risk factors (e.g., 
parity, milk production, pathogen, and bacteriological cure) should be recorded on 
well managed farms and can be utilized for predicting herd clinical mastitis episodes 
(Jamali et al., 2018). Ideally, well-managed herds should have an incidence rate of 





Some scientists hypothesize that the persistence of some environmental 
intramammary infections may be caused by the formation of biofilms and not re-
infection (Melchior, 2011). Of all the mastitis pathogens capable of producing 
biofilms in intramammary infections, contagious Staph. aureus is the best studied. 
However, more information regarding biofilms from environmental mastitis 
pathogens E. coli and Strep. uberis has become available. Costa et al. (2014) 
demonstrated that 27 strains of E. coli isolated from cases of bovine mastitis were 
capable of biofilm formation under conditions mimicking a mastitis-infected 
mammary gland. Four other bovine mastitis E. coli strains were able to form biofilms 
on mammary alveolar cells in vitro (Source Silva, 2014). Strep. uberis biofilms have 
formed under similar conditions of Staph. aureus in vitro and results suggest that they 
are composed of similar components and structure (Almeida et al., 2006; Varhimo et 
al., 2010). Although no histological samples have yet to be found in bovine udders, 
the ability of E. coli and Strep. uberis to form biofilms under similar environmental 
conditions may suggest that the physiological barrier of a biofilm helps contribute to 
the chronic infection. 
 
Innate Immune Response to Mastitis 
One third of all clinical cases of bovine mastitis are caused by Gram-negative 
bacteria and nearly 25% of these cases result in culling or death of the animal. These 
incidence rates are only expected to rise over the future as producers strive for lower 
herd SCC. Promptness and magnitude of recruitment of innate immune cells to the 





Cueninck, 1979; Hill, 1981). Neutrophils are the primary innate cell recruited (~90%) 
and have a prominent role in the defense of the mammary gland against bacterial 
infections (Paape et al., 2002). Cytokines, such as tumor necrosis factor-alpha, 
granulocyte-macrophage colony-stimulating factor and interleukins 1-beta, 6 and 8, 
from mammary epithelial cells and macrophages attract neutrophils in circulation 
(Jung et al., 1995; Boudjellab et al., 1998). Following extravasion into the lumen of 
the mammary gland, neutrophils utilize phagocytosis, reactive oxygen species (ROS) 
production, and extracellular traps to eradicate the pathogens. The bactericidal 
activity of neutrophils is inefficient in milk as compared to their activity in blood 
(Russell and Reiter, 1975; Paape et al., 2003). Milk lacks some compounds that favor 
neutrophil function, such as glucose for energy and oxygen for ROS production 
(Newbould, 1970; Goldberg et al., 1995; Mehrzad et al., 2001). In addition, the fat 
globules and casein present in milk are shown to interfere with neutrophil efficiency 
in vitro by reducing phagocytosis and oxidative burst activity (Russell and Reiter, 
1975; Paape and Guidry, 1977; Paape et al., 2003).  
Although these factors directly affect the main functions of neutrophils, 
bacteria can alter other factors of the neutrophil’s ability to combat infection. The 
optimal concentration of neutrophils required to exert effective bactericidal activity is 
approximately 106 cell/mL milk (Paape et al., 1963; Herbelin et al., 1997). Increased 
concentrations beyond this assessment do not result in improved bactericidal activity 
and are linked to detrimental side effects caused by excessive pro-inflammatory and 
enzymatic activity of the neutrophils (Leijh et al., 1979; Paape et al., 2003). 





bacteria species and stage of infection. Neutrophils mobilized against E. coli, Staph. 
aureus and Strep. agalactiae-caused mastitis are fairly efficient even several hours 
post infection. However, neutrophils are less efficient toward mastitis caused by 
Strep. uberis and Mycoplasma species (Brownlie et al., 1979; Leigh and Field, 1994). 
Severity of E. coli mastitis is highly dependent upon the speed at which neutrophils 
are mobilized. A delayed appearance following infection correlates with high 
bacterial concentrations in the milk and severe mastitis (Vandeputte-van Messom et 
al., 1993). In comparison¸ Strep. uberis induces a delayed response for neutrophil 
recruitment via interleukin-8 from mammary epithelial cells in vitro (Wellnitz et al., 
2006). Following the neutrophils’ primary defense of the mammary gland, 
macrophages that are normally present in the healthy mammary gland assist with the 
bactericidal activity through phagocytosis of the pathogen and processing of the 
antigen for presentation to lymphocytes to begin the adaptive portion of the immune 
response (Politis et al., 1991; Fitzpatrick et al., 1992). 
 
Mastitis Treatment with Antibiotics 
Following the emergence of mastitis symptoms or lactation cessation, 
antibiotics serve as the conventional mastitis treatment (Oliver et al., 2011). 
Currently, there are only two classes of antibiotics approved by the FDA for the 
treatment of bovine mastitis: 1) new generation β-lactams (cell wall disruptors based 
on penicillin as the parent drug) such as cephalosporin, ceftiofur and cephapirin, and 
2) licosamides (transpeptidation protein synthesis inhibitors based on clindamysin) 





information on the package label authorizes the approved usage), the drug may either 
be delivered via intramammary or systemic routes. Intramammary delivery is the 
most common method and accounts for the greatest use of antibiotics on dairy 
operations (US Department of Agriculture, 2007) as most farmers treat clinical 
mastitis cases based on symptoms (Hoe and Ruegg, 2006). However, across the stated 
spectrum of organisms that cause mastitis, bacterial pathogens are only isolated from 
~50% of clinical mastitis cases (Olde Riekerink et al., 2008; Oliveira and Ruegg, 
2014), resulting in the administration of antibiotics to cases that may not be of 
husbandry or clinical benefit, and therefore contributing to the problem of 
inappropriate antibiotic use and possible development of emerging drug resistant 
bacterial strains.  
Growing concerns regarding antibiotic use and the potential for antimicrobial 
resistance from their use have led to the need to develop alternative strategies to 
antibiotics for controlling and perhaps even preventing mastitis, a measure which 
should reduce the use of antibiotics on-farm (Bannantine et al., 2013). Although no 
compelling evidence exists that the use of antibiotics to treat mastitis has resulted in 
increased prevalence of resistant pathogens on dairy farms in the US (Erskine et al., 
2002; Rajala-Schultz et al., 2004; Pol and Ruegg, 2007), the White House released 
the National Action Plan for Combating Antibiotic Resistant Bacteria (2015) which 
calls for improved antibiotic stewardship, increased resistance monitoring, and 
accelerated antimicrobial therapy research and development in human and animal 





exists for improvements and development in the use of new antimicrobials for 
treatment of bovine mastitis.  
 
Alternative Antimicrobials 
Many old and novel anti-mastitis strategies have been explored recently to 
help treat and control mastitis. Although many therapies were explored decades ago, 
the call for reduced antibiotic use in veterinary applications has renewed exploration. 
Some success has been found in vaccinations for bovine mastitis. Although the 
“miraculous” vaccine to prevent all mastitis remains elusive, the E. coli J5 vaccine 
has been successful at reducing the incidence rate and severity of coliform mastitis by 
70-80% (Hogan et al., 1992). Some vaccines for S. aureus have also shown promise, 
but their effectiveness is dependent upon several factors, such as age of cow and 
environmental conditions (Hoedemaker et al., 2001; Kazemi et al., 2014). 
Nanoparticles have demonstrated to be useful in biomedical applications as delivery 
vehicles for antimicrobial agents, such as silver and nitric oxide nanoparticles to 
inhibit S. aureus and E. coli mastitis pathogens (Dehkordi et al., 2011; Cardozo et al., 
2014). Photodynamic therapies also utilize nanoparticles to cause pathogen death. 
Administered light activates photosensitive compounds in the nanoparticles that 
convert oxygen to ROS, such as oxygen and hydroxide radicals. Both of these ROS 
are capable of killing a broad spectrum of pathogens and have shown to effectively 
inhibit growth of coagulase negative Staphylococcus and Strep. dysgalactiae 
(Hamblin, 2016; Parra Sellera et al., 2016; Moreira et al., 2018). Of the many 





bacteriophages and natural compound citrus oil appear very promising as a potential 
new therapy for bovine mastitis. 
 
Lysins 
An antimicrobial alternative currently being developed is the bacteriolytic cell 
wall hydrolases known as lysins (or endolysins). Bacteriophages evolved a system to 
allow progeny phages to exit the bacterium by utilizing proteins that weaken the 
bacterial cell wall and results in bacteria lysis. These enzymes, lysins, target the 
integrity of the cell wall by attacking one of the 4 major peptidoglycan bonds. Most 
lysins lack signal sequences and require additional help to pass the cytoplasmic 
membrane and access the cell wall. Secondary molecules, called holins, are inserted 
into the cytoplasmic membrane and form holes that lead to general membrane 
disruption (Wang et al., 2003). This allows the lysin enzymes in the cytoplasm to 
access the peptidoglycan and cause cell lysis. 
For nearly a century, scientists have been aware of the lytic activity of phages. 
Recently, whole phages have been used to control staphylococcal strains known to 
cause bovine mastitis (Kwiatek et al., 2012). Although the phage therapy does not 
irritate the cow nor cause an increase is milk SCC (O’Flaherty et al., 2005), phage 
therapy was unsuccessful at curing experimentally-induced Staph. aureus mastitis 
(Gill et al., 2006), as preformed antiphage immunoglobulins likely inactivated the 
phage. Lysin enzymes can be inactivated by antibodies similarly to whole phage; 
however, repeated exposure to lysin enzymes in hyperimmune rabbit serum raised 





2003; Rashel et al., 2007; Fischetti, 2010). Repeated dosing of lysin enzymes in mice 
raised their IgG antibody titer against the enzyme to low, but measurable levels; 
however, enzyme lysis activity against the target pathogen remained constant 
(Loeffler et al., 2003; Rashel et al., 2007). Given the high binding affinity of the 
enzyme for its substrate in the bacterial cell wall (Loessner et al., 2002), it is likely 
that this affinity is higher than the antibody’s affinity for the enzyme. It may be 
possible for lysin enzymes to be used repeatedly to control bacterial infections. 
In many instances, lysins only target one species of bacteria. Most lysins are 
active against Gram-positive bacteria as exogenous application of the lysin must be 
able to make direct contact with the cell wall carbohydrates and peptidoglycan. The 
outer membrane of the Gram-negative bacteria prevents this interaction. One of the 
most potent endolysins to date is the streptococcal-specific lysin, PlyC, which was 
characterized and purified from the virulent C1 bacteriophage. Many bacteriophage-
derived enzymes require microgram or milligram quantities to cause a multiple-log 
reduction of target bacteria over several minutes; whereas, PlyC requires only 
nanogram quantities and seconds to neutralize 107 CFU (Nelson et al., 2001).  
Previous research spanning over 50 years has shown that PlyC can rapidly 
lyse streptococci groups A, C, and E, in addition to Strep. uberis and Streptococcus 
equi (Strep. equi; Krause, 1957; Nelson et al., 2001). Based on biochemical, 
biophysical and genetic data, PlyC is a multimeric holoenzyme composed of two 
subunits, PlyC subunit A (PlyCA) and PlyC subunit B (PlyCB). PlyCB is an octamer 
that is responsible for binding to the bacterial cell wall. PlyCA is  responsible for the 





histidine-dependent aminohydrolases/peptidases catalytic domain that cleaves 
between N-acetyl muramic acid and L-alanine (Nelson et al., 2006), and 2) glycoside 
hydrolase catalytic domain that cleaves between N-acetyl glucosamine and N-acetyl 
muramic acid (McGowan et al., 2012). The unique structure of PlyC may be linked to 
its enhanced activity as compared to other lytic enzymes.  
Over the past 20 years, PlyC has been utilized in numerous applications with 
no reported adverse effects. In mice, PlyC was administered orally as a prophylaxis to 
prevent colonization of Streptococcus pyogenes (Strep. pyogenes) and as a treatment 
for the elimination of a Strep. pyogenes infection in heavily colonized mice (Nelson 
et al., 2001). PlyC has demonstrated further bactericidal activity against Strep. 
pyogenes by eradicating biofilms (Shen et al., 2013), and targeting and controlling 
intracellular infections in human epithelial cells in vitro (Shen et al., 2016). As a 
germicidal spray disinfectant, PlyC was able to significantly reduce or eradicate 
Strep. equi, the causative agent of equine strangles, from a variety of materials and 
under conditions that mimic a horse stable (Hoopes et al., 2009). The variety of 
applications and the retention of lysin activity suggests that PlyC may be useful for 
treatment of bovine mastitis caused by streptococcal species.  
 
Citrus Oil 
Citrus oil is one of many well-known essential oils in the world with noted 
antimicrobial properties. The oil is produced by cells within the rind of lemon and 
orange fruit and is typically extracted as a by-product of juice production. 





composition that occurs as a result of regional and seasonal changes (Shaw and 
Coleman, 1974). Regardless of variation, limonene accounts for ~90% of citrus oil’s 
composition with various alcohols, esters, aldehydes, hydrocarbons, ketones and 
oxides accounting for the remaining portion (Bauer et al., 2001; Moufida and 
Marzouk, 2003). Limonene has demonstrated antimicrobial activity against food-
borne pathogens; however, citral and linalool have been identified as the active 
compounds contributing to the bactericidal activity of citrus oil (Fisher and Phillips, 
2006). 
A potential alternative to traditional antimicrobial pharmaceutical drugs may 
be found in orange/citrus oil obtainable from by-products that otherwise might be 
discarded. Citrus oil has been used in the food industry for decades to create citrus 
flavor. In the past decade, citrus oil use has expanded to meat preservations as the 
compounds in the oils act as natural antioxidants and deter the growth of bacteria and 
other pathogens that cause spoilage and disease (Mahato et al., 2017). When applied 
directly to meat, citrus oil and it components have displayed bacteriostatic and 
bactericidal characteristics towards E. coli, S. aureus, and Mycobacterium bovis 
(Fisher and Phillips, 2006; Crandall et al., 2012; Muthaiyan et al., 2012; Federman et 
al., 2016). The antimicrobial properties of citrus oil are not limited to surface 
applications of meat but are active within milk in vitro, as well. A relatively low 
concentration (0.1% vol/vol) inhibited and reduced bacterial growth of E. coli and S. 
aureus in pasteurized milk (Dabbah et al., 1970). As many of the pathogens that 





characteristics of citrus oil may also prove useful for deterring and eliminating these 
species from the mammary gland. 
Citrus oil components have shown some success as an alternative 
antimicrobial treatment for bovine mastitis. Relatively low concentrations of citrus oil 
components dissolved in dimethylsulfoxide (DMSO) have successfully inhibited and 
eradicated S. aureus planktonic and biofilm bacterial growth, and did not demonstrate 
long term cytotoxic effects on cultured bovine mammary cells (Aiemsaard et al., 
2011; Garcia et al., 2015; Federman et al., 2016). However, the use of DMSO in dairy 
cattle is prohibited by the FDA (US Department of Health and Human Service and 
Public Health Service, 2015). A suitable, alternative solvent for citrus oil components 
is ethanol as it can maintain oil solubility at low concentrations and its use is not 
prohibited.  
One of the active components contributing to citrus oil antimicrobial activity 
is citral, an ethanol-soluble chemical known as 3,7-dimethyl-2,6-octadienal. As a 
monoterpenoid aldehyde, citral has two isomers, geranial and neral, that are also 
commonly identified in the leaves and fruits of several plant species, including basil, 
lemon, lime, lemongrass, orange and bergamot (Hyldgaard et al., 2012). The strong, 
lemon odor of geranial and sweeter, more subtle lemon aroma of neral make citral a 
valuable compound that is widely used as a flavoring agent in food and drink and 
scent in perfumery (Nannapaneni et al., 2009; Choi et al., 2010). Beyond a scent and 
flavor, citral has favorable anti-inflammatory (Ortiz et al., 2010) and anti-corrosive 





antibacterial (Onawunmi, 1989; Lu et al., 2016; Shi et al., 2016) and antifungal (De 
Bona Da Silva et al., 2008) properties. 
Another active component of citrus oil is linalool, 3,7-dimethl-1,6-dien-3-ol. 
Also ethanol-soluble and a monoterpenoid, it has been isolated from over 200 
different species of fruits, flowers and spice plants for many commercial applications, 
mainly for its pleasant scent (floral, with a touch of spiciness; Furia, 1980). Linalool 
has anti-oxidant (Mitic-Culafic et al., 2009; Mehri et al., 2015) and analgesic 
properties (Peana et al., 2004; Linck et al., 2009), in addition to low cytotoxic effects 
on human endothelial cells and fibroblasts (Prashar et al., 2004). Although linalool 
has not been directly tested on immune cells, restrained rats exposed to aerosolized 
linalool had decreased neutrophils and lymphocytes in their blood, suggesting 
possible stress reduction and anti-inflammatory effects (Nakamura et al., 2009). 
 
Antimicrobial Assessment of Citrus Oil 
Assessment of new antimicrobials, such as citrus oil, against pathogenic 
species typically begins with in vitro analyses to determine minimum concentrations 
to inhibit and reduce growth. Minimum inhibitory concentration (MIC) is defined as 
the lowest concentration of antimicrobial that prevents a clear suspension of bacteria 
(105 CFU/mL) from becoming turbid after overnight incubation (Levison and 
Levison, 2009). Minimum bactericidal concentration (MBC) of an antimicrobial 
product is the lowest concentration that reduces bacterial density by 99.9% (3-log10). 
For bacteriostatic antimicrobials, the MIC and MBC will be the same; whereas, the 





subjective measures, they illustrate the effective concentrations of the antimicrobial 
that deter and stop exponential bacterial growth. 
 MIC and MBC are useful tools for assessing new antimicrobial 
pharmacokinetics; however, they only assess antimicrobial susceptibility for 
planktonic and rapid bacterial growth. The most common known mastitis-causing 
bacterial pathogens (Staph. aureus, Strep. uberis, E. coli and Strep. agalactiae) can 
also create biofilms, structured bacterial communities that adhere to an inert or living 
surface (Melchior et al., 2006b). Biofilms can constitute a protected mode of growth 
for bacteria in hostile environments as a self-produced extracellular polysaccharide 
matrix allows bacterial cells to adhere to one another and create a multi-layer 
community. Bacterial cells within the biofilm structure are protected from antibiotics 
and the host-immune system, therefore promoting survival of the bacteria, recurrence 
of the infection and contributing to antibiotic resistance (Olson et al., 2002). Similar 
to planktonic bacterial growth, biofilm susceptibility to antimicrobials is measured 
through biofilm minimum inhibitory concentration (BMIC) and bactericidal 
concentration (BMBC), as well as minimum biofilm eradication concentration 
(MBEC). Susceptibility of the planktonic bacteria released from the biofilm during 
the overnight incubation is used to determine the BMIC and BMBC; whereas, the 
susceptibility of the biofilm bacteria after dislodging them from the biofilm through 
sonication and recovering them in media is used to determine the MBEC (Melchior et 






The objectives of this dissertation are: 1) determine the effects of PlyC on 
bovine blood neutrophils, 2) determine the MIC, MBC, MBEC against isolated 
mastitis pathogen E. coli strain P4, and effects on bovine blood neutrophils for citrus 
oil and its primary components, and 3) determine the effects of primary citrus oil, 
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Mastitis is the leading cause of antimicrobial use on dairy farms. The potential 
for antimicrobial resistance has led to the examination of alternative strategies for 
controlling mastitis. One such alternative is PlyC, a potent peptidoglycan hydrolase 
derived from the streptococcal C1 bacteriophage that causes targeted lysis of the cell 
wall of Streptococcus uberis. At a concentration of 1.0 μg/mL, recombinant PlyC can 
induce lytic activity, suggesting that a low dose may successfully eliminate infection. 
We evaluated the dose effect of PlyC (1-50 µg/mL) on cytotoxicity and oxidative 
response on bovine blood polymorphonuclear leukocytes (PMN) obtained from 
twelve healthy, mid-lactation primiparous dairy cows. Following incubation at 0.5 
and 2 h, cytotoxicity was characterized by measuring lactate dehydrogenase release 
from isolated cells. Oxidative burst response was characterized as the intensity of 
chemiluminescence produced in the interaction of ROS generated in response to 0 or 
1.6 µg/mL phorbol 12-myristate-13-acetate (PMA) with a luminescent substrate with 
and without addition to PlyC to the incubation matrix. Data were analyzed as a 
complete randomized block design using mixed model procedures. Cytotoxicity of 
PlyC was not affected by concentrations up to 50 µg/mL. As expected, PlyC 
cytotoxicity on PMN varied across incubation time with greater cell toxicity 
measured at 2 h incubation as compared to 0.5 h and is primarily attributed to the 
short life of PMN ex vivo. Concentrations of PlyC up to 50 µg/mL did not affect 
oxidative response; however, oxidative response was affected by incubation time and 
PMA concentration. In summary, varying doses of PlyC are non-toxic as estimated by 





ROS production in bovine PMN. These early observations support continued work on 
the potential for application of this novel agent in combating mastitis. 
 
Short Communication 
In regard to dairy production, mastitis is the most common and economically 
significant disease. The estimated losses to producers in the United States exceed $2 
billion per year with each clinical case costing approximately $179 (Cha et al., 2011). 
A wide variety of pathogens cause bovine mastitis including bacteria, yeast and algae. 
Pathogens arising from the environment, such as Strep. uberis and E. coli, are 
consistently being detected and reported as a leading cause of subclinical and clinical 
bovine mastitis throughout the world (National Mastitis Council, 2015). Strep. uberis 
is the most prevalent environmental streptococci mastitis pathogen (Jayarao et al., 
1999). The number of cases caused by Strep. uberis continues to rise even in well-
managed herds as typical mastitis control practices, such as teat disinfection and 
sanitary housing and milking environments, are less effective at preventing Strep. 
uberis-associated mastitis (Kromker et al., 2014).  
The most common treatment strategy for clinical cases of Strep. uberis is the 
administration of intramammary antibiotics, such as cephalosporin β-lactams or 
penicillin G (Oliver et al., 2011). Growing concerns regarding antibiotic use and the 
potential for antimicrobial resistance from their use have led to the need to develop 
alternative strategies to antibiotics for controlling mastitis, a measure which should 
reduce the use of antibiotics on-farm (Bannantine et al., 2013). An antimicrobial 





as lysins (or endolysins). These bacteriophage-derived enzymes rapidly and 
specifically lyse bacteria when applied exogenously (Fischetti, 2006). One of the 
most potent endolysins to date is the streptococcal-specific PlyC. Previous research 
spanning over 50 years has shown that PlyC can rapidly lyse streptococci groups A, 
C, and E in addition to Strep. uberis and Strep. equi and has been shown to protect 
mice from streptococcal infection challenge (Krause, 1957; Nelson et al., 2001). 
Therefore, the use of recombinant PlyC is an appealing choice for use against select 
streptococcal species in bovine mastitis, such as Strep. uberis. 
Following bacteria entry into the mammary gland, circulating PMN, i.e. 
neutrophils, are the first cells recruited and then represent the most predominant 
somatic cell type (Burvenich et al., 1994). The initial magnitude of the PMN response 
will often dictate the overall effect of mastitis on the cow, as increased recruitment of 
PMN and greater overall PMN activity will decrease the mastitis duration and 
severity (Rainard and Riollet, 2003a).  Stimuli from mammary cells and invading 
pathogens activate PMN to eliminate the pathogens through the production of 
chemical mediators, such as ROS, and phagocytosis (Miller et al., 1993). As an 
alternative to pathogenic bacteria, PMA is commonly used to stimulate cellular 
aspects of oxidative metabolism as PMA structure stimulates PMN similarly normally 
associated with bactericidal activity in vitro (Rinaldi et al., 2007; Freitas et al., 2009). 
Although intramammary administration of PlyC is a promising new 
management strategy to treat Strep. uberis mastitis, the effects of PlyC on the bovine 
immune response remain unknown. Delayed appearance or decreased immunological 





antibiotic alternatives should not interfere with or harm the host immune response if 
they are to be considered useful. The objective of this study was to evaluate any 
cytotoxicity effects of PlyC on bovine PMN and on the PMN oxidative response to 
activation. We hypothesized that various concentrations of PlyC would be non-toxic 
and not alter the inflammatory response of bovine PMN in vitro. 
All procedures involving the use of live animals were approved in accordance 
with the regulations and guidelines set forth by the USDA-Beltsville Animal Care and 
Use Committee. Twelve, healthy primiparous Holstein cows were used for this study. 
To be eligible, cows must have had a composite milk SCC <100,000 cells/mL and 
cows must not have been treated for clinical signs of mastitis or any other disease 
during early lactation. Eligible cows were housed in tie-stalls and individually fed a 
standard TMR to meet the requirement of lactating dairy cows at the USDA-
Beltsville Agricultural Research Center. Free choice water was available and cows 
were fed ad-libitum twice daily to ensure 5-10% refusals. All cows were milked twice 
daily at 0730 and 1630 h (hour) in a double-8 herring bone parlor with milk records 
recorded monthly. Cows averaged 178 ± 4 days in milk (DIM) and 40.7 ± 1.3 kg milk 
per day (d) at time of sampling. 
Recombinant PlyC was expressed and purified as previously described 
(Nelson et al., 2001, 2006). Briefly, E. coli were grown at 37°C in baffled flasks to an 
optical density 600 = 1 in LB-Miller medium (Luria broth containing 10 g/L sodium 
chloride) supplemented with 100 µg/mL ampicillin. Expression of PlyC was induced 
by the addition of arabinose (0.25%). After growth for an additional 4 h at 37°C, cells 





ceramic hydroxyapatite resin (Bio-Rad Laboratories Inc., Hercules, CA) to remove 
cellular debris. As approximately 80-90% pure protein was eluted by 1 M sodium 
phosphate pH 7.2, a second round of purification by S200 size exclusion 
chromatography was performed to remove endotoxin. All PlyC used in experiments 
was produced in a single batch. 
Approximately 200 mL of blood was collected via jugular venipuncture from 
each cow into 15 mL centrifuge tubes with conical bottoms (VWR, Radnor, PA) 
containing 2.5 mL of acid-citrate dextrose solution (Sigma-Aldrich Inc., St. Louis, 
MO) and stored on ice. Blood samples were processed within 1 h of collection. 
Isolation of PMN, viability and cell differentiation were performed using endotoxin 
free materials and reagents as previously described (Garcia et al., 2015). Viability of 
PMN was 96% with a cell differential of 91% PMN. Cells were counted by a TC20 
Automated Cell Counter (Bio-Rad Laboratories) then diluted to concentrations 
appropriate for each assay.  From each cow, 800 µL of PMN were placed in 24-well 
cell culture plates and treated with 200 µL of 0, 1, 10 or 50 µg of PlyC in 1X 
phosphate buffer solution (PBS). Plates were incubated for 0.5 or 2 h at 37°C, 95% 
relative humidity and 5% CO2. 
The cytotoxicity of PlyC on PMN was determined in vitro. Prior to incubation 
with PlyC, PMN were diluted to ~3.5 × 105 per mL for analysis of PMN cytotoxicity 
using the CytoTox 96 non-radioactive, colorimetric assay (Promega, Madison, WI) to 
quantify lactate dehydrogenase production. Relative cytotoxicity was calculated per 





Within incubation period and cow, each PlyC treatment was performed in triplicate 
(coefficient of variance [CV] = 2.66%). 
The oxidative response of PMN was determined by luminol 
chemiluminesence assay to quantify ROS production. Neutrophils were diluted to 
~3.0 × 106 per mL prior to incubation with PlyC. Following incubation with PlyC for 
0.5 or 2 h, 0.5 mL of media was transferred into round-bottomed, glass 7 mL tubes. 
Tubes were placed into a heating block and incubated at 37°C for 10 min. In a 
separate reaction tube (2 per each media tube), 900 µL of assay buffer (0.5 mM CaCl2 
in Hank’s balanced salt solution) and 100 µL of a 5 mM luminol solution in dimethyl 
sulfoxide (Sigma-Aldrich) were added and placed in the heating block. At the end of 
the incubation, either 40 µL of sterile water or 1.6 µg/mL PMA (Sigma-Aldrich) 
solution were added to each media tube. Tubes were gently vortexed and returned to 
the heating block. After heating, 40 μL from the media tube was transferred to the 
reaction tube. Tubes were again lightly vortexed and immediately placed in the 
luminometer (AutoLumat LB 953, Berthold Technologies, Germany) to measure 
relative chemiluminescence for 20 minutes. Within incubation period, PMA 
concentration and cow, each PlyC treatment was performed in duplicate (CV = 
11.96%).  
Experimental units and the corresponding sample size of cows that were used 
in this study have been determined using the POWER procedure of SAS (SAS/STAT 
version 9.3; SAS Institute Inc., Cary, NC) for a one-way analysis of variance. Means 
and average standard deviation values for PMN oxidative response and PlyC 





are parameters included in the procedure: 1) an alpha set at 0.05 to declare 
significance, 2) an 80% probability of detecting a difference in treatment means, 3) a 
15,000 luminescence unit difference between treatment means, and 4) an average 
standard deviation value of 6,400. The procedure was repeated for PlyC cytotoxicity 
with a 15 unit difference between means and an average standard deviation value of 
7. Based on the results of the power analyses, it was concluded that at least 10 cows 
are required for this study. 
 Response variables were analyzed as a complete randomized block design 
using the PROC MIXED procedure of SAS. Sources of variation within the model 
included effects of PlyC concentration, PMA concentration (oxidative response 
model only), and incubation time as well as 2- and 3-way interaction among the main 
effects. Cow was designated as a random effect in the model. Separation of least 
square means for significant effects was accomplished using the PDIFF option in the 
MIXED procedure. Significance was declared at P ≤ 0.05. Data are presented as least 
squares mean ± standard errors of the mean. 
In the current study, concentrations of purified PlyC at 1, 10 and 50 μg/mL 
did not have a cytotoxic effect on PMN relative to cells incubated in buffered solution 
(P = 0.41) as cytotoxicity remained constant across concentrations (47-55%). These 
results indicate that PlyC, even at high doses, is not toxic to bovine PMN in vitro. 
Incubation time increased PlyC cytotoxicity by 25% from 0.5 h to 2 h (44.6 vs. 55.0 ± 
2.8%; P = 0.01) as expected, given the relatively short half-life of circulating PMN is 
6-8 h (Summers et al., 2010). However, incubation time across PlyC concentrations 







Figure 2.1: Least square means and standard errors for bovine neutrophil cytotoxicity for neutrophils 
incubated in vitro for 0.5 and 2 hours in various concentrations of recombinant streptococcal C1 phage 
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  Respiratory oxidative burst activity of PMN incubated with purified PlyC 
was determined by luminol chemiluminescence following 0.5 or 2 h of incubation 
and stimulation by 0 or 1.6 µg/mL PMA. Similar to cytotoxicity, respiratory burst 
was not affected by PlyC concentrations up to 50 µg/mL (P = 0.52) and relative 
luminescence remained constant (29,838 ± 3,315 relative luminescence units), 
indicating that PlyC may not interfere with the function of PMN during the 
inflammatory response in vivo. As expected, increasing PMA concentration from 0 to 
1.6 µg/mL increased PMN respiratory burst response (21,514 vs. 38,162 ± 4,585 
relative luminescence units; P < 0.01) reflecting the activation of nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase and production of ROS, 
superoxide anions and hydrogen peroxide, similarly to that of an invading pathogen 
(White et al., 1984; Kobayashi et al., 2005). However, PMN respiratory response to 
PMA was dependent upon incubation time with longer incubation decreasing 
respiratory burst of PMN incubated with 1.6 µg/mL PMA (P < 0.01; Figure 2.2A). 
The overall decreased respiratory burst response across incubation time reflects the 
increased cell deterioration and death observed in the PMN cytotoxicity analysis. The 
relative oxidative burst of PMN was not affected by PlyC concentration across 
incubation time (P = 0.45) although relative luminescence was numerically lower 








Figure 2.2: Least square means and standard errors for the bovine neutrophil oxidative response as 
determined by luminol chemiluminescence at 0.5 or 2 h of incubation and stimulated by 0 or 1.6 
µg/mL phorbol 12-myristate-13-acetate (PMA) solution in various concentrations of recombinant 
streptococcal C1 phage lysin (PlyC). A) Oxidative response and incubation time across PMA 
concentration; B) oxidative response and incubation time across PlyC concentration. a-c Means with 
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The growing concern for antibiotic resistance and improved stewardship has 
fueled the drive to find antibiotic and antimicrobial alternatives. Bacteriophage lysins 
have been used successfully in a variety of models to control pathogenic antibiotic 
resistant and tolerant bacteria found on mucosal surfaces and infected tissues. The 
streptococcal-specific endolysin PlyC is unique among the lysins and has rapid lethal 
effect in vitro (McGowan et al., 2012) and in vivo (Nelson et al., 2001). Relatively 
low concentrations of PlyC have successfully been used for disinfection of Strep. equi 
(1 μg/mL; Hoopes et al., 2009) and degradation of Streptococcus pyogenes biofilms 
(5 μg/mL; Shen et al., 2013) in addition to the prevention and elimination of Strep. 
pyogenes in mice (0.01 µg; Nelson et al., 2001). These effective concentrations were 
substantially lower than those examined in the current study. Concentrations of PlyC 
up to 50 μg/mL were nontoxic on bovine PMN. These results demonstrate that the 
lytic activity of PlyC does not target bovine PMN and that effective concentrations of 
PlyC would likely be nontoxic to recruited neutrophils during mastitis. 
Recruited neutrophils use many techniques to destroy pathogenic bacteria that 
have entered the mammary gland, such as phagocytosis, extracellular traps and 
degranulation (Summers et al., 2010). ROS produced and released during the 
respiratory burst response aid in bacterial destruction and clearance of the infection. 
Again, high concentrations of PlyC (up to 50 μg/mL) did not affect the respiratory 
burst response of bovine PMN. Effective, lower concentrations of PlyC would likely 






To our knowledge, this study is the first to characterize the effects of 
bacteriophage-based lytic enzyme PlyC on bovine PMN. Results show that high 
concentrations of PlyC are non-toxic and do not impede the oxidative response of 
bovine PMN. Future studies investigating the use of PlyC as an alternative therapy for 
treatment of mastitis are warranted. 
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Chapter 3: Citrus Oil and its components antimicrobial activity 
and effects on bovine blood neutrophils. 
 
Introduction 
 Mastitis is one of the most important diseases in dairy cattle of which E. coli 
is a major pathogen (Shpigel et al., 1998). Neutrophils are the primary innate cell 
recruited (~90%) and have a prominent role in the defense of the mammary gland 
against bacterial infections (Paape et al., 2002). Many studies have demonstrated that 
the promptness and magnitude of neutrophil recruitment can influence the severity 
and outcome of mastitis caused by E. coli mastitis (Hill, 1981; Vandeputte-van 
Messom et al., 1993). Disruption of neutrophil abilities and efficiency to address the 
mastitis infection can have severe consequences on mastitis outcome (Rainard, 2003). 
Despite an apparently good antimicrobial susceptibility in vitro, the cure of 
diseased animals from E. coli mastitis is often disappointing. Current available 
antibiotics have minimal effect on shortening the duration of the intramammary 
infection as some cases will spontaneously cure, while others result in recurrent 
clinical infections (Smith et al., 1985). Decreased antibiotic responsiveness, antibiotic 
overuse and misuse, and increased awareness of antibiotic resistant bacteria entering 
the human food chain prompted further exploration into alternative antimicrobial 
therapies. Natural compounds, such as those derived from plants, have biologically 
active agents with antimicrobial action. Plant-derived compounds have the potential 
of not inducing resistance after prolonged exposure (Chandra et al., 2017) or creating 





A potential alternative to traditional antimicrobial pharmaceutical drugs used 
to treat bovine mastitis may be found in orange/citrus oil obtained from by-products 
that otherwise might be discarded. Citrus oil has been used in the food industry for 
decades to create citrus flavor (Hyldgaard et al., 2012). In the past decade, citrus oil 
use has expanded to meat preservations as the compounds in the oil act as natural 
antioxidants and deter the growth of bacteria and other pathogens that cause spoilage 
and disease (Mahato et al., 2017). When applied directly to meat, citrus oil and it 
components have displayed bacteriostatic and bactericidal characteristics towards E. 
coli, Staph. aureus, and Mycobacterium bovis (Fisher and Phillips, 2006; Crandall et 
al., 2012; Muthaiyan et al., 2012; Federman et al., 2016). The antimicrobial properties 
of citrus oil are not limited to surface applications of meat but are active within milk 
in vitro, as well. A relatively low concentration (0.1% vol/vol) inhibited and reduced 
bacterial growth of E. coli and Staph. aureus in pasteurized milk (Dabbah et al., 
1970). As many of the pathogens that cause food spoilage are also pathogenic species 
for bovine mastitis, these characteristics of citrus oil may also prove useful for 
deterring and eliminating these species from the mammary gland. 
 MIC and MBC are useful tools for assessing new antimicrobial 
pharmacokinetics; however, they only assess antimicrobial susceptibility for 
planktonic and rapid bacterial growth. E. coli can also create biofilms, structured 
bacterial communities that adhere to an inert or living surface (Melchior et al., 
2006b). Biofilms can constitute a protected mode of growth for bacteria in hostile 
environments as a self-produced extracellular polysaccharide matrix allows bacterial 





within the biofilm structure are protected from antibiotics and the host-immune 
system, therefore promoting survival of the bacteria, recurrence of the infection and 
contributing to antibiotic resistance (Olson et al., 2002). Similar to planktonic 
bacterial growth, biofilm susceptibility to antimicrobials is measured through BMBC 
and MBEC.  
Citrus oil components have shown some success as an alternative 
antimicrobial treatment for bovine mastitis. Relatively low concentrations of citrus oil 
components dissolved in DMSO have successfully inhibited and eradicated Staph. 
aureus planktonic and biofilm bacterial growth, and did not demonstrate cytotoxic 
effects on cultured bovine mammary cells or neutrophils (Aiemsaard et al., 2011; 
Garcia et al., 2015; Federman et al., 2016). However, the use of DMSO in dairy cattle 
is prohibited by the FDA (US Department of Health and Human Service and Public 
Health Service, 2015). A suitable, alternative solvent for citrus oil components is 
ethanol as it can maintain oil solubility at low concentrations and its use is not 
prohibited. It is prudent to reassess the effects of citrus oil dissolved in ethanol as the 
antioxidant effects and synergy of DMSO with antimicrobials may have altered the 
effects of citrus oil (Ansel et al., 1969; Mi et al., 2016). 
 Therefore, the objectives of this study are to determine the effects of citrus oil 
components on 1) the susceptibility of environmental pathogen, E. coli, and 2) bovine 
blood neutrophil viability and oxidative burst activity in vitro. We hypothesize that 
citrus oil components in ethanol will demonstrate inhibitory and eradication 





demonstrated in past studies, and will not be cytotoxic or inhibit neutrophil oxidative 
burst response. 
 
Methods and Materials 
Animals and Sampling Procedure 
All procedures involving the use of live animals were approved in accordance 
with the regulations and guide-lines set forth by the University of Maryland Animal 
Care and Use Committee. Twelve healthy, mid-lactation multiparous Holstein cows 
were used for this study. To be eligible, cows must have had a composite milk SCC < 
200,000 cells/mL, culture negative milk, and cows must not have been treated for 
clinical signs of mastitis or any other disease during their current lactation. Cows 
averaged 141 ± 17 DIM and 37.9 ± 1.3 kg milk/d at time of sampling. Cows were 
housed and fed in free stalls at the Central Maryland Regional Extension Center dairy 
unit in Clarksville, MD and milked twice daily at 0700 and 1900 h. Cows were fed 
daily a standard total mixed ration formulated to meet nutritional requirements 
(National Research Council, 2001) and 10% refusals. 
Before milk sampling during the morning milking, a California Mastitis Test 
(CMT) was performed to ensure low SCC in each quarter of the cow. Teats were 
dipped in foam germicide containing hydrogen peroxide, stripped and wiped dry with 
single service, cloth towels. A teat end from a negative CMT quarter was rigorously 
cleaned with cotton balls containing 70% ethanol and approximately 50 mL of 
foremilk was aseptically collected. Milk samples were immediately refrigerated after 





jugular venipuncture from each cow into 15 mL centrifuge tubes with conical bottoms 
containing 2.5 mL of acid-citrate dextrose solution and stored on ice. Blood samples 
were processed within 1 h of collection. 
 
Bacteria Growth 
The strain used in this study was the E. coli strain P4, serotype O32:H37 
(graciously provided by Dr. Jo Ann Van Kessel, US Department of Agriculture), 
which was isolated from a clinical mastitis case (Bramley, 1976) and is widely used 
to induce experimental mastitis (Blum et al., 2017).The strain is capable of causing 
clinical mastitis in cows and extracellular biofilms on murine mammary epithelial 
cells (Shpigel et al., 2008). The strain was maintained in a stock on lyophilization 
medium at -20°C. A stock of bacteria was sub-cultured at 37°C in brain-heart 
infusion broth (Sigma Aldrich) for 6-8 h then transferred and cultured in tryptic soy 
broth (TSB) for 18-24 h. Following incubation, inoculated TSB were stored at 4°C. 
Sub-cultures of TSB were diluted in pyrogen-free PBS and plated on MacConkey 
agar and 5% sheep blood agar plates to determine CFU/mL and detect possible 
contamination before performing antimicrobial susceptibility assays. 
 
Antimicrobials 
Citrus oils (Sigma-Aldrich Inc., St. Louis, MO) and citrus oil components 
citral (Sigma-Aldrich), linalool (Sigma-Aldrich), limonene (Sigma-Aldrich) and 
valencene (Sigma-Aldrich) were diluted in ethanol and sterile PBS on a percentage 





to oil concentrations were maintained at 7:1 (vol/vol) for oil solubility. An ethanol-
only treatment was also examined to determine the effects of ethanol on E. coli 
growth with ethanol concentrations mirroring those used to maintain the oils in 
solution. 
 
Citrus Oil Minimum Inhibitory and Bactericidal Concentration 
Citrus oil and its various functional components were tested to determine the 
MIC required for E. coli P4. The inoculated TSB was diluted to 8 x 106 CFU/mL 
using pyrogen-free PBS and 100 μL of broth was transferred to sterile, 24-well flat 
bottom plates. All oil and ethanol concentrations were added (100 μL) in triplicate. 
On each plate, single well controls included broth, broth plus E. coli (no treatment), 
PBS and ethanol.  Plates (n = 4) were incubated at 37°C for 24 h. MIC was defined as 
the amount of antimicrobial that inhibited visible growth in the well as measured by 
optical density at 595 nm (Pankey and Sabath, 2004). A subculture of 100 μL was 
taken from the wells displaying inhibited growth and plated on sheep’s blood 5% agar 
and MacConkey, in duplicate. The lowest concentration of the treatment that 
prevented growth on the agar plates was taken as the MBC (Baskaran et al., 2009). 
MIC and MBC were also obtained in bovine milk for citral, linalool, and 
ethanol using the same concentrations and plating procedure in 24-well, flat bottomed 
plates. All bovine milk was cultured on MacConkey agar and 5% sheep blood agar at 
37°C for 24 h to confirm the absence of pathogenic bacteria prior to use of the milk as 





concentrations and controls were plated in duplicated on MacConkey agar and 5% 
sheep blood agar plates to determine MIC and MBC. 
 
Minimum Biofilm Eradication Concentration 
 Measurements of the antimicrobial susceptibility of E. coli P4 biofilms was 
performed in the MBEC biofilm assay (Innovotech, Edmonton, AB, Canada) 
according to the manufacturer’s instructions. This method facilitates formation of 
biofilms on the surface of pegs that can be exposed to an antimicrobial challenge for 
determination of the susceptibility of E. coli P4 biofilms for citrus oil components 
(Ceri et al., 1999).  
 Following establishment of the E. coli P4 inoculum, the TSB was diluted 
further in sterile TSB and culture-negative milk. In a sterile 96-well plate, biofilms 
were established by adding 150 µL of inoculated, diluted media to each well 
(~5.0×105 CFU) and covered with a lid containing 1 peg per well. The plate was 
incubated at 37°C for 16 h at approximately 95% humidity on a plate shaker at 110 
revolutions per minute (VWR Scientific, Buffalo Grove, IL) to obtain ~105 CFU 
biofilm growth on each peg. Biofilm formation was determined by removing 3 pegs 
from the lid with sterilized pliers and placing each peg in TSB in a new 96-well plate. 
The biofilm was disrupted from the peg by sonicating the plate on high for 30 
minutes, serial diluting the TSB in sterile PBS and spot plating 20 μL from each 






 Once biofilms are established on the MBEC pegs, the pegged-lid was 
transferred to another 96-well plate containing 2-fold dilutions of the antimicrobial 
treatments citral, linalool, and corresponding ethanol-only. The plate was incubated at 
37°C for 12 h to correspond with the average time between treatments when cows are 
milked twice daily. After incubation, the lid with pegs was removed, rinsed in PBS 
and placed in a second 96-well plate containing TSB. Planktonic bacteria released 
from the biofilm in the first 96-well plate with the antimicrobial treatments (20 µL) 
was transferred to a third plate containing 180 µL of TSB to determine BMBC. The 
second 96-well plate was sonicated, as previously described, to dislodge the biofilm 
to measure antimicrobial susceptibility of the E. coli bacteria (MBEC). The BMBC 
and MBEC plates were incubated at 37°C for 24 h and visible growth in the plates 
was measured at 650 nm in a 96-well plate reader (Bio-Rad Laboratories, Hercules, 
CA). All treatment dilutions were performed in duplicate on the 96-well plates and 
the experiment were repeated 3 times, similarly to previous studies (Ceri et al., 1999; 
Olson et al., 2002).  
 
Blood Neutrophil Isolation and Incubation 
 Isolation of blood neutrophils, viability and cell differentiation were 
performed using endotoxin free materials and reagents as previously described 
(Garcia et al., 2015). Cells were counted by a TC20 Automated Cell Counter (Bio-
Rad Laboratories) then diluted to concentrations appropriate for each assay. Isolated 
cells were 94.4 ± 1.3% neutrophils with 92.2 ± 0.8% being viable. From each cow, 1 





citral or linalool dissolved in ethanol and PBS with a 7:1 ethanol to oil ratio (vol/vol) 
to maintain oil solubility. A control treatment of ethanol-only was also tested to 
discern the effects of ethanol on bovine neutrophils. Plates were incubated for 2 h at 
39°C, 95% relative humidity and 5% CO2. 
 
Cytotoxic Effects on Bovine Blood Neutrophils 
 The cytotoxic effects of citral, linalool and ethanol on neutrophils was 
determined in vitro. Prior to incubation with oils and ethanol, neutrophils were diluted 
to ~3.5 × 105 cells/mL for analysis of oil and ethanol cytotoxicity using the CytoTox 
96 non-radioactive, colorimetric assay (Promega, Madison, WI) to quantify lactate 
dehydrogenase release from cells. Relative cytotoxicity was calculated per 
instructions provided by the manufacturer. 
 
% Cytotoxicity =  
Experimental − Effector Spontaneous − Target Spontaneous
Target Maximum − Target Spontaneous
 × 100 
 
Neutrophil Oxidative Burst Response 
The oxidative response of neutrophils was determined by luminol 
chemiluminesence assay to quantify ROS production. Neutrophils were diluted to 
~3.0 × 106 per mL prior to incubation with citral and linalool. Following incubation 
with citrus oil fractions for 2 h, 0.5 mL of media was transferred into round-
bottomed, glass 7 mL tubes. Tubes were placed into a heating block and incubated at 





buffer (0.5 mM CaCl2 in Hank’s balanced salt solution) and 100 µL of a 5 mM 
luminol solution in DMSO; Sigma-Aldrich) were added and placed in the heating 
block. At the end of the incubation, either 40 µL of sterile water or 1.6 µg/mL PMA 
(Sigma-Aldrich) solution were added to each media tube. Tubes were gently vortexed 
and returned to the heating block. After heating, 40 μL from the media tube was 
transferred to the reaction tube. Tubes were again lightly vortexed and immediately 
placed in the luminometer (AutoLumat LB 953, Berthold Technologies, Germany) to 
measure relative chemiluminescence for 20 min. Each oil and ethanol treatment 
concentration was performed in duplicate within PMA concentration and cow. 
 
Statistical Analysis 
The number of animals required to observe significant changes in neutrophil 
oxidative burst response and cytotoxicity of citrus oil components dissolved in 
ethanol was determined using the POWER procedure for a one-way analysis of 
variance in SAS version 9.4 (SAS/STAT version 9.4; SAS Institute Inc., Cary, NC). 
Experimental response means and standard deviation values were based on a previous 
study where the effects of citrus oil components dissolved in DMSO on bovine blood 
neutrophils were examined. It was concluded that 10 animals would produce 85% 
probability to detect a difference between treatment means (alpha = 0.05) in 
neutrophil response and citrus oil component cytotoxicity. The number of biological 
and experimental replicates for MIC, MBC, BMBC and MBEC was determined from 





Response variables, cytotoxicity and oxidative burst chemiluminescence, were 
analyzed as a complete randomized block design using the PROC MIXED procedure 
of SAS (SAS/STAT version 9.4). Sources of variation within the model included oil 
concentration and a separate ANOVA was run for each oil treatment type. Cow was 
designated as a random effect in the model. Separation of least square means for 
significant effects was accomplished using the TUKEY option in the MIXED 
procedure. Significance was declared at P ≤ 0.05. Data are presented as least squares 
mean ± standard error of the mean. 
 
Results 
Citrus Oil Minimum Inhibitory and Bactericidal Concentrations 
In TSB, citrus oil, and citrus oil fractions limonene and valencene 
concentrations up to 4,000 μg/mL did not inhibit E. coli P4 growth (Figure 3.1). The 
ethanol-only treatment performed similarly, as concentrations required to maintain 
the citrus oil and citrus oil fractions in solution (up to 7% vol/vol ethanol) did not 
affect bacterial growth. Fractions of citral and linalool inhibited bacterial growth at 
1,786 μg/mL and 1,740 μg/mL, respectively. These concentrations were slightly 
greater than the MIC observed when citrus oils and its fractions were dissolved in 
DMSO. Limonene, valencene and citrus oils performed similarly with much higher 
MIC values than those of citral (447 μg/mL) and linalool (870 μg/mL) when 









Figure 3.1: Minimum inhibitory concentrations of citrus oil and citrus oil fractions when dissolved in 































Similar MIC and MBC values were determined for citral and linalool when E. 
coli was cultured in bovine milk (Table 3.1). Citral demonstrated a similar 
concentration for MIC (1786 μg/mL) and a slightly greater concentration for MBC 
(3,572 μg/mL) as compared to TSB. Linalool required much higher concentrations 
than citral to inhibit growth (3,480 μg/mL) and kill the E. coli (3,480 μg/mL). The 
concentration of ethanol required to maintain citral and linalool solubility did not 
appear to influence MIC and MBC as the concentration of ethanol required to inhibit 
growth and neutralize E. coli (70% vol/vol) was much greater than the concentrations 








Table 3.1: Minimum inhibitory (MIC) and bactericidal (MBC) concentrations (μg/mL) for citral, 







MIC 1,786  3,480  70 







Citrus Oil Fractions Minimum Biofilm Eradication Concentration 
Escherichia coli biofilms were successfully established and averaged 2.945 × 105 
CFU/mL when grown in TSB and 2.994 × 105 CFU/mL in bovine milk. Lower 
concentrations of citral were required to eradicate the established E. coli biofilms and 







Table 3.2. Minimum concentrations (μg/mL) for citrus oil fractions and ethanol-only against 











   
Milk 2,775 5,440 8.75 
TSB 1,390 2,720 8.75 
Minimum Bactericidal 
Concentration 
   
Milk 5,550 5,440 8.75 







Citrus Oil Fractions Cytotoxicity 
The CytoTox 96 colorimetric assay did not accurately measure bovine 
neutrophil cytotoxicity in treatments containing high concentrations of ethanol 
(greater than 11.2%; Figure 3.2). It is likely that the high concentrations of ethanol 
inhibited or interfered with the lactate dehydrogenase and therefore it could not be 
accurately assessed. Ethanol concentrations up to 11.2% vol/vol did not exhibit 
cytotoxic effects on bovine neutrophils. Citral and linalool had minimal cytotoxic 
effects, as well. Citral concentrations (ranging from 447 to 3,573 μg/mL) were 
slightly more toxic to neutrophils than PBS; the buffered saline; however, the 
increased cytotoxicity is biologically negligible. Similar results were observed for 









Figure 3.2: Least square means and standard errors for the cytotoxicity of bovine neutrophils 
incubated in various concentrations of citrus oil fractions, citral (A) and linalool (B). a-b Means with 
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Concentration P < 0.01







Bovine Neutrophil Oxidative Burst Response 
Overall oxidative burst response (i.e., respiratory burst) was measured through 
relative luminescence as ROS reacted with luminol (Figure 3.3). Citral concentrations 
ranging from 893 to 1,786 μg/mL and linalool concentration 1,740 μg/mL increased 
relative oxidative response as compared to neutrophils in PBS. Relative ethanol 
concentrations required to maintain citral and linalool in solution did not impact 
oxidative response, indicating that citral and linalool may be aiding overall neutrophil 
respiratory burst. High concentrations of citral (44,600 μg/mL) and linalool (43,500 
μg/mL) did not affect oxidative burst, as compared to neutrophils incubated with 
PBS; however, the relative ethanol content required to maintain the oil solubility 







Figure 3.3: Least square means and standard errors for the bovine neutrophil oxidative response as 
determined by luminol chemiluminescence following incubation in various concentrations of citral 










































































































Citrus oil has demonstrated bacteriostatic and bactericidal effects across many 
applications and pathogens in food science and as a possible antimicrobial for 
treatment of infectious disease. Because of their complexity and variation, no general 
statement can be made as to citrus oil’s antimicrobial properties. The degree of 
growth inhibition of bacterial growth varies considerably with the pathogen and 
system tested. Regardless of variation, citrus oil is composed primarily of limonene 
(~90%) and various alcohols, esters, aldehydes, hydrocarbons, ketones and oxides 
(Bauer et al., 2001; Moufida and Marzouk, 2003). This study has demonstrated that, 
using the MIC method, that components of citrus oil have greater bacteriostatic and 
bactericidal properties against E. coli strain P4 than the oil alone. In TSB, citral and 
linalool required lower concentrations than citrus oil and other major components to 
inhibit E. coli growth. Fisher and Phillips (2006) observed similar results as limonene 
and citrus oil had limited antimicrobial activity against E. coli (O157:H7) and other 
food-borne pathogens; whereas, linalool and citral inhibited growth at lower 
concentrations in broth.  
Many essential oils, including citrus oil, citral and linalool, have demonstrated 
anti-biofilm activity. Several in vitro studies have shown that bacteria growing in a 
biofilm can become more resistant to the effects of antimicrobial agents as compared 
to planktonic growing bacteria of the same strain (Ceri et al., 1999; Olson et al., 
2002). Mastitis associated with bacterial mammary infections may be caused by 
biofilms due to the observed shift in antimicrobial susceptibility (Melchior, 2011).  





intracellular communication mechanism like quorum sensing. Inhibition or 
dysregulation of quorum sensing can directly affect biofilm activity. Linalool and 
essential oils with high concentrations of linalool, such as coriander, display anti-
quorum sensing activity in Campylobacter species biofilms (Duarte et al., 2016). 
Concentrations required to disrupt formed biofilms in the current study were 1-2× 
greater than those required to inhibit growth and eradicate planktonic bacteria. 
Similar results were observed for oregano, thyme and cinnamon essential oils against 
several different bacteria, as concentrations similar to MIC and MBC values were 
able to eradicate biofilms (Szczepanski and Lipski, 2014). 
Few have tested the antimicrobial effects of citrus oil in milk. Dabbah et al. 
(1970) observed that orange oil was an effective antimicrobial in skim milk with a 1-2 
log reduction of food borne pathogens. In pasteurized milk, the effects of the citrus 
oils on bacteria growth varied with the fat content of the milk. Increased fat content 
resulted in decreased antimicrobial effectiveness of the oils (Fisher and Phillips, 
2008). Holley and Patel (2005) speculate that the higher concentrations of lipids in 
the milk created a layer around the bacteria and prevented the oils from interacting 
with the bacteria. Similar results were observed in the current study as citral and 
linalool MIC, MBC and MBEC values for E. coli were greater in milk as compared to 
broth.  
The action mechanism for essential oils’ antimicrobial activity is not fully 
understood. Evidence of changes in intracellular adenosine triphosphate (ATP) 
concentration, reduced cellular pH and cell membrane hyperpolarization, in addition 





Cronobacter sakazakii (Gram-negative rod related to Enterobacter species) following 
exposure to citral suggest that it damages the cell membrane by binding to the surface 
and interacting with cell target molecules (Shi et al., 2016). However, this action was 
not observed when Candida species were incubated with citral (Clerya et al., 2014). 
The antimicrobial activity of linalool is speculated to involve penetration and 
disruption of the lipid fraction of the cellular membrane of Staph. aureus and E. coli 
(Trombetta et al., 2005). In addition, there is limited knowledge regarding the 
mechanisms that lead to tolerance against essential oils and their components and the 
extent the tolerance can occur in microorganisms. There is some evidence that strains 
of E. coli can become less susceptible to essential oils from repeated use, but MIC 
values increased (2-14×) only to a limited extent (Walsh et al., 2003). Gomes Neto et 
al. (2015) observed the involvement of gene regulation in increasing tolerance of E. 
coli following repeated exposure of two essential oils at sub-inhibitory 
concentrations.  
Ethanol and DMSO have known antimicrobial properties that inhibit bacterial 
growth of many pathogens at low concentrations. The soluble nature of ethanol is 
effective at dissolving surface lipids and denaturing proteins of pathogens, including 
most bacteria, fungi and many viruses. The most effective concentration is 70% 
vol/vol ethanol because of osmotic pressure; pathogens become dehydrated as the 
osmotic pressure across the cell membrane is disrupted, leading to cell death 
(Pohorecky and Brick, 1988). Similarly, Ansel et al. (1969) noted that 12% vol/vol 
DMSO inhibited over 90% growth of E. coli. As a solvent, DMSO affects the 





affecting the nature of the compound. With cinnamon oil, DMSO partitions the oil 
between two different phases and ultimately limits is microbial effects (Hili et al., 
1997). In contrast, limonene dissolved in DMSO has an increased droplet size that 
results in higher antimicrobial activity, likely due to higher contact between the 
droplet and microbial membrane (Van de Vel et al., 2017). This effect on droplet size 
of the oil in the DMSO emulsion may account for the increased antimicrobial activity 
observed in citrus oils and its components as compared with those dissolved in 
ethanol. The concentration of ethanol required to maintain effective concentrations of 
citral and linalool in solution did not appear to impact the overall bacteriostatic and 
bactericidal effects of the oil on E. coli.  
Citral and linalool are generally recognized as a safe food additive and are 
approved by the Food and Drug Administration for use in foods (Food and Drug 
Administration, 2018). In addition, they have been registered by the European 
Commission for use a flavoring in foodstuffs because its use does not present risk to 
the health of the consumer (Burt, 2004). Given the possibility of utilizing the oils as 
an intramammary therapy for E. coli mastitis, there may not be a need for milk 
withdrawal as there are few risks associated with ingestion of the oils. In regard to the 
cow, the oils do not appear to have any severe negative impacts on bovine immune 
cells either. In the current study, citral and linalool and the concentration of ethanol 
required to maintain them in solution were mildly cytotoxic toward bovine blood 
neutrophils, but did not negatively impact neutrophil oxidative burst response. Others 





either (Federman et al., 2016), suggesting that citrus oils and their components are not 
likely to harm nor interfere with cells in the bovine mammary gland. 
Conclusion 
Citral and linalool maintained much of their antimicrobial activity when 
dissolved in ethanol as compared to DMSO and were effective in milk as well as 
broth. In addition, citral and linalool did not cause severe harm or interference with 
bovine neutrophils. The ability of citral and linalool to inhibit proliferation of E. coli 
P4 planktonic cells and biofilms highlight their potential as alternative antimicrobial 
therapies for bovine mastitis. 
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Chapter 4: Citral is an ineffective intramammary therapy for 
experimentally-induced Escherichia coli mastitis in dairy cows. 
Introduction 
Citrus oil is one of many well-known essential oils in the world with noted 
antimicrobial properties (Gomes and Henriques, 2016). The oil is produced by cells 
within the rind of lemon and orange fruit and is typically extracted as a by-product of 
juice production. Centrifugation produces a cold-pressed oil that is primarily terpenes 
with a varying composition that occurs as a result of regional and seasonal changes 
(Shaw and Coleman, 1974). Regardless of variation, limonene accounts for ~90% of 
citrus oil’s composition with various alcohols, esters, aldehydes, hydrocarbons, 
ketones and oxides accounting for the remaining portion (Bauer et al., 2001; Moufida 
and Marzouk, 2003). Limonene has demonstrated antimicrobial activity against food-
borne pathogens; however, citral and linalool have been identified as the active 
compounds contributing to the bactericidal activity of citrus oil (Fisher and Phillips, 
2006). 
Citral is chemically known as 3,7-dimethyl-2,6-octadienal. As a cyclic 
unsaturated monoterpene aldehyde, citral has two isomers, geranial and neral, that are 
commonly identified in the leaves and fruits of several plant species, including basil, 
lemon, lime, lemongrass, orange and bergamot (Hyldgaard et al., 2012). The strong, 
lemon odor of geranial and sweeter, more subtle lemon aroma of neral make citral a 
valuable compound that is widely used as a flavoring agent in food and drink and 





flavor, citral has favorable anti-inflammatory (Ortiz et al., 2010) and anti-corrosive 
effects (Korenblum et al., 2013) in addition to the increasing evidence to its 
antibacterial (Onawunmi, 1989; Lu et al., 2016; Shi et al., 2016) and antifungal (De 
Bona Da Silva et al., 2008) properties.  
Bovine mastitis, an inflammatory condition of the mammary gland, is often 
caused by bacterial intramammary infection and treated with antibiotic therapies 
directly infused into the mammary gland. Current available antibiotics have minimal 
effect on shortening the duration of many intramammary infections as some cases 
will spontaneously cure, while others result in recurrent clinical infections (Smith et 
al., 1985). With the growing national concern of antibiotic overuse, misuse and 
resistance, many have sought alternative approaches for controlling and treating 
mastitis in dairy cows. The bacteriostatic and bacteriocidal activity of citrus oils and 
its active component, citral, are natural antimicrobials that may serve as an alternative 
to antibiotic therapy. Citrus oils have demonstrated bacteriostatic and bactericidal 
activity toward mastitis pathogens, such as Staph. aureus, E. coli, and Mycoplasma 
bovis (Fisher and Phillips, 2006; Crandall et al., 2012; Muthaiyan et al., 2012; 
Federman et al., 2016) and effective concentrations do not appear to disrupt the 
bovine innate immune response (Garcia et al., 2015), nor harm bovine mammary 
epithelial cells (Federman et al., 2016). Our experiments with low concentrations of 
citral dissolved in ethanol have demonstrated similar results as compared to citrus oils 
emulsified in DMSO. Low concentrations of citral were nontoxic for bovine 
neutrophils and did not disrupt their oxidative burst response in vitro. E. coli P4 





citral as low concentrations inhibited growth and eradicated the bacteria in broth and 
milk. Citral is also generally recognized as safe food additive and is approved by the 
Food and Drug Administration for use in foods (Food and Drug Administration, 
2018). In addition, citral has been registered by the European Commission for use a 
flavoring in foodstuffs because its use does not present risk to the health of the 
consumer (Burt, 2004). Therefore, it is prudent to test citral as an antimicrobial 
therapy for bovine mastitis in vivo.  
The objectives for the current study are to 1) determine the effects of citral as 
an intramammary therapy in healthy, multiparous dairy cows challenged with E. coli 
mastitis, and 2) compare the effectiveness of citral to a common intramammary 
antibiotic therapy (ceftiofur hydrochloride) for E. coli mastitis and no treatment. We 
hypothesize that citral will be an effective intramammary treatment for E. coli 
mastitis that will not impede the dairy cow. 
 
Materials and Methods 
Animals 
 All procedures involving the use of live animals were approved in accordance 
with the regulations and guidelines set forth by the University of Maryland Animal 
Care and Use Committee. Eighteen, healthy multiparous Holstein cows in mid-
lactation (>100 DIM) were used for this study. All eligible cows displayed no signs of 
clinical disease, had no previous history of mastitis during the current lactation, and 





detectable bacterial growth (i.e. bacteriologically negative for culturable pathogens) 
in their milk prior to enrollment in the study.  
Once eligible, cows were blocked based on parity and milk production, 
removed from the herd and housed in individual tie-stalls. Cows were fed twice daily 
a standard TMR formulated to meet requirements and 10% refusals. Cows had ad 
libitum access to water and were milked twice daily at 0700 and 1900 h. Eligible and 
enrolled study cows were quarantined from the rest of the herd and milked last in 
order to prevent the transfer of E. coli mastitis. After a one-week adjustment period, 
aseptic quarter milk samples were collected and analyzed again for SCC and 
bacteriological status to re-confirm eligibility. 
Bacteria and Intramammary Inoculation 
 To reproduce clinical signs of mastitis, the strain used in this study was the E. 
coli strain P4, serotype O32:H37. The strain was maintained in a stock on 
lyophilization medium at -20°C. A stock of bacteria was sub-cultured at 37°C in 
brain-heart infusion broth (Sigma Aldrich, St. Louis, MO) for 6-8 h then transferred 
and cultured in TSB (Sigma Aldrich) for 18-24 h. Following incubation, inoculated 
TSB was stored at 4°C. Sub-cultures of TSB were diluted in pyrogen-free PBS and 
plated on MacConkey and 5% sheep blood agar plates to determine CFU per milliliter 
and detect possible contamination. Immediately before intramammary inoculation, a 
final concentration of 200 CFU/mL bacterial suspension was prepared in pyrogen-
free PBS. The total volume of inoculant was 4 mL (~800 CFU total). 
Intramammary inoculation with the bacterial suspension was performed 





per eligible cow to be inoculated. The teat end from this quarter was rigorously 
cleaned with cotton balls wetted with 70% ethanol. The bacterial suspension was 
infused into the rear quarter via a sterile, disposable syringe fitted with a sterile teat 
cannula using the partial insertion method as recommended by the National Mastitis 
Council (National Mastitis Council, 2004). Immediately following inoculation, teats 
were immersed in a teat dip cup post-milking teat disinfectant containing 1% iodine 
with lanolin. 
Intramammary Treatment 
 Infected quarters were randomly assigned to an intramammary experimental 
therapy. After infection was established (24 h post-inoculation, d 1), each inoculated 
rear quarter (n = 6 quarters/treatment) was randomly assigned to receive 1 of 3 
treatments following recommendations of the National Mastitis Council (National 
Mastitis Council, 2004) for 4 consecutive d that included either:  
1) 0% citral (100% sterile PBS; CON) in 10 mL administered 2X/d,  
2) 1.0% citral (90% PBS, 9% ethanol, 1% citral vol/vol; 8,930 μg citral; OO) in 
10 mL administered 2X/d, or  
3) ceftiofur hydrochloride (125 mg; Spectramast LC, Zoetis, Parsippany-Troy 
Hills, NJ; AB) in 10 mL administered 1X/d, as per label instruction (morning 
milking only).  
Ceftiofur hydrochloride is an antibiotic commonly used to treat E. coli bovine 
mastitis in lactating dairy cows. The concentration of citral used in the current study 
was determined in experiments conducted in Chapter 4 that analyzed MIC, MBC, and 





Prior to administration of the treatments, teats were rigorously cleaned with 
cotton balls wetted with 70% ethanol. All treatments were administered using the 
partial insertion method. Immediately following treatment, teats were immersed in a 
post-milking teat disinfectant containing 1% iodine with lanolin.  
Health Examinations 
 Physical exams (including heart rate, respiration rate, rectal temperature, 
appetite, dehydration, lethargy, posture, and diarrhea), mammary palpation exams 
(including udder swelling, redness, and soreness) and clinical score were performed 
daily for 7 consecutive d post-inoculation, then once per week until 35 d. Clinical 
score was recorded on a 5-point scale (National Mastitis Council, 2004):  
1 = normal milk and normal quarter,  
2 = normal quarter but milk was questionable,  
3 = normal quarter but abnormal milk,  
4 = a swollen quarter and abnormal milk, and  
5 = swollen quarter, abnormal milk, and systemic signs of infection. 
Sampling Procedure 
 Feed intake, feed refusals, and milk production were recorded daily. Quarter 
foremilk samples were collected from all quarters during the morning milking on d -
7, -4 and 0 prior to inoculation and d 7 and 35 post inoculation to identify bacterial 
status. Milk samples were collected twice daily (prior to morning and afternoon 
milkings) from the infected rear quarter for 7 consecutive d following inoculation (d 





cure. Half units for d indicate samples taken during afternoon milkings. Milk samples 
were analyzed for concentrations of fat, protein, other solids and somatic cells by 
Lancaster DHIA (Manheim, PA). SCS was calculated by log2(SCC/100) + 3 where 
SCC is in units of 1,000 cells/mL. 
Milk Culture 
 Quarter foremilk samples for culture were collected aseptically according to 
National Mastitis Council (2004) recommendations. These samples (100 µL) were 
plated using the swirl plate method onto tryptic soy agar containing 5% sheep’s blood 
and MacConkey agar plates using a sterile, disposable L-shaped cell spreader. If 
needed, the samples were serially diluted with sterile, endotoxin-free PBS to facilitate 
colony counting. Milk was allowed to dry before inverting the plates. Inoculated 
plates were incubated at 37°C for a maximum of 48 h and analyzed for the presence 
of mastitis-causing pathogens (National Mastitis Council, 2004). Colonies of E. coli 
were counted and bacterial concentrations in milk were calculated. A minimum of 3 
CFU will be used as the criteria to identify a positive isolation for any one pathogen; 
three or more types of pathogens isolated from the same culture were identified as 
contaminated. An infection was considered to be present if the sample contained 
greater than 1 CFU/mL of E. coli in 2 of 3 consecutive samples. 
Statistical Analysis 
Experimental units and the corresponding sample size of cows that were used 
in this study have been determined using the POWER procedure of SAS (SAS/STAT 





values for log10 SCC data were calculated from a previously conducted pilot study. 
The following are parameters included in the procedure: 1) an alpha set at 0.05 to 
declare significance, 2) an 85% probability of detecting a difference in treatment 
means, and 3) a projected standard deviation value of 0.3. Based on the results of the 
power analyses, it was concluded that at least 5 cows per treatment are required for 
this study. Studies with similar objectives have reported a similar number of 
biological replicates (Oldham and Daley, 1991). To be conservative and considerate 
of the high variance between cow responses during a mastitis challenge, at least 6 
cows were assigned to each treatment. 
 Response variables were analyzed as a complete randomized design using the 
MIXED procedure of SAS (SAS/STAT version 9.4; SAS Institute Inc., Cary, NC) 
with the repeated measure of d relative to intramammary E. coli challenge (d 0). Milk 
CFU of E. coli were transformed to log10 values for statistical analysis. Sources of 
variation within the model included treatment, time relative to the intramammary 
challenge and the interaction of treatment across time. Separation of least square 
means for significant effects was accomplished using the PDIFF option in the 
MIXED procedure. Chi-square analysis was used to test the significance of 
differences in the number of quarters cured in each treatment group at d 35 following 
inoculation by utilizing the GENMOD procedure and LOGIT model of SAS 
(SAS/STAT version 9.3; Oldham and Daley, 1991). Statistical differences were 
declared as significant at P < 0.05 and trends toward significance are discussed at 






Results and Discussion 
All eighteen cows were successfully infected with E. coli P4 and displayed 
clinical symptoms within 12 h following inoculation. Incubation of the prepared 
inoculum revealed that cows were inoculated with an average of 837 CFU total. Milk 
CFU was log10 transformed and not affected by treatment over the 35 d sampling 
period (P = 0.56), or first week post challenge (P = 0.36). Milk CFU concentrations 
were similar to previous studies utilizing E. coli strain P4 as an experimental mastitis 
challenge (Herry et al., 2017). Differences between the AB treatment (ceftiofur 
hydrochloride), OO treatment (citral) and CON treatment were expected, but not 
observed in the current study. The antibiotic treated cows had numerically lower milk 
bacteria count as compared to the cows receiving the control treatment (Figure 4.1). 
This suggests that the experimental mastitis challenge model was likely successful 
and would have revealed a treatment effect with a greater number of cows assigned to 
the study. Many E. coli mastitis challenge trials utilized more than 10 cows per 
treatment and observed treatment effects between the experimental treatment and 
control (Shpigel et al., 1997; Vangroenweghe et al., 2004a; b). With greater 







Figure 4.1: Least square means and standard errors for log10-transformed CFU/mL of Escherichia 
coli strain P4 in milk from infected rear quarters following inoculation (d 0). Treatment was 
implemented 24 h post inoculation with one of three treatments for 4 consecutive days: 125 mg 
ceftiofur hydrochloride daily (AB), sterile saline twice daily (CON), or 8,930 μg citral (1% vol/vol) 
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Observed local and systemic signs in the present study were similar to those 
described by others using the same model and could not be differentiated from natural 
cases of clinical E. coli mastitis (Hill, 1981; Lohuis et al., 1990; Pyorala et al., 1994; 
Shpigel et al., 1997). Somatic cell count quickly rose and peaked between d 1 and 2 
following inoculation. Following the onset of treatments on d 1 post inoculation, SCC 
differed by treatment across time (P = 0.06; Figure 4.2). Afternoon milking samples 
(0.5 d units) during the treatment period, d 1-4, tended to vary by treatment (P = 0.01; 
Table 4.2). The AB treatment tended to decrease SCC as compared to OO and CON 
on d 1.5. In addition, OO tended to decrease SCC as compared to AB and CON on d 







Figure 4.2: Least square means and standard errors for milk somatic cell count (SCC, cells/mL 
×1,000) from infected rear quarters following inoculation (d 0; ~800 CFU Escherichia coli P4). 
Treatment was implemented 24 h post inoculation with one of three treatments for 4 consecutive days: 
125 mg ceftiofur hydrochloride daily (AB), sterile saline twice daily (CON), or 8,930 μg citral (1% 
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The anti-inflammatory properties of citral may have decreased SCC in milk 
following the administration of the treatment following the morning milking on d 2 
and 3. Systemic administration of citral in rats decreased inflammation and edema in 
paws irritated by a carrageenan injection (Ortiz et al., 2010) and decreased body 
temperature following an injection of LPS (Carlini et al., 1986). A potential 
mechanism may be through a reduced inflammatory state for cells. Macrophages are 
resident immune cells in the bovine mammary gland that, when activated, are 
essential for neutrophil recruitment (Rainard and Riollet, 2003b). In LPS stimulated 
murine macrophages, citral reduced nitric oxide and tumor necrosis factor α 
production and inhibited inducible nitric oxide synthase, cyclooxygenase 2 and 
nuclear factor kappa B protein expression (Lin et al., 2008). The activation of nuclear 
factor kappa B is a major signaling pathway for cytokine and chemokine production 
that drive the onset of the mammary inflammatory cascade (Boulanger et al., 2003; 
Bannerman, 2009). Reduced inflammation and immune cell recruitment and activity 
is not necessarily wanted in E. coli mastitis as cure rate and animal survival is highly 
correlated with the rate of neutrophil recruitment and inflammatory response 
(Burvenich et al., 2003). However, the anti-inflammatory effects of citral may be 
useful when cows are in chronic inflammatory states if they can be sustained. The 
inflammatory effects on SCC in the present study were not sustained and only 
observed in the afternoon milking. The short period of time (10 h) between treatment 
administration following the morning milking and afternoon sampling suggest that 
the anti-inflammatory effects are transient. Citral degrades rapidly in acidic 





The anti-inflammatory effects may have also been diluted as milk production between 
afternoon to morning milk sampling was numerically greater (5-7 kg) than the period 








Table 4.1: Dry matter intake, and milk production and characteristics among treatment groups for 
week 1 following inoculation. Cows were infected with ~800 CFU of Escherichia coli P4 into one 
rear mammary quarter and treated 24 h later for 4 consecutive days. 
 Treatment1  P-value 





23.5 21.8 20.9 1.3 0.37 0.29 
       
Milk Production, kg/d 
Morning 17.7 16.8 16.2 1.5 0.76 0.02 
Afternoon 11.2 11.7 9.8 0.9 0.27 0.01 
Daily Total 30.0 27.0 26.4 2.3 0.52 0.78 
       
Milk Components, % 
Fat 4.04 4.48 4.02 0.53 0.79 0.82 
Protein 3.28 3.51 3.59 0.15 0.35 0.63 
OS 5.09 5.04 5.00 0.10 0.82 0.84 
1Treatments: AB = 125 mg ceftiofur hydrochloride, 1×/day; CON = sterile, endotoxin-free buffered 





Other intramammary characteristics did not differ across treatments. Clinical 
score, SCS and the ratio of logCFU and SCC did not vary by treatment and treatment 
across time (Table 4.2). The severity of infection, quantified through the ratio of 
logCFU and SCS, varied by treatment across time (P = 0.01; Table 4.2) for the first 
week following inoculation; however, there were no discernable trends of the ratio 
over time by treatment. Mammary and milk characteristics were similar in related E. 






Table 4.2: Intramammary infection characteristics among treatment groups for week 1 following 
inoculation. Cows were infected with ~800 CFU of Escherichia coli P4 into one rear mammary 
quarter and treated 24 h later for 4 days. 
 Treatment1  P-value 
Item AB CON OO SEM TRT TRT × Day 
Clinical 
Score2 
2.75 2.85 3.00 0.15 0.46 0.73 
logCFU3 1.36 1.78 1.83 0.25 0.36 0.85 
SCC4 5,800 6,380 5,620 670 0.70 0.06 
SCS5 7.84 7.98 7.69 0.24 0.69 0.98 
SCC ratio6 0.007 0.012 0.010 0.004 0.68 0.99 
SCS ratio7 0.289 0.307 0.300 0.044 0.95 0.01 
1Treatments: AB = 125 mg ceftiofur hydrochloride, 1×/day; CON = sterile, endotoxin-free buffered 
solution, 2×/day; OO = 8,930 μg citral (1% vol/vol), 2×/day 
2Score Range 1-5 (National Mastitis Council, 2004):  
1 = normal milk and normal quarter,  
2 = normal quarter but milk was questionable,  
3 = normal quarter but abnormal milk,  
4 = a swollen quarter and abnormal milk, and  
5 = swollen quarter, abnormal milk, and systemic signs of infection. 
3Escherichia coli log10(CFU/mL) 
4Somatic Cell Count, cells/mL (×1,000) 
5Somatic Cell Score  
6SCC ratio = log10(CFU/mL) / SCC 







Dry matter intake, milk production and milk components were not affected by 
treatments. Cows treated with AB numerically ate more feed across the sample 
period. Subsequently, cows also produced more milk as compared to CON and OO 
treated cows in the first week and across the 35 d sampling period (Table 4.1; Figure 
4.3). Similar results regarding milk production, milk components and DMI were 
observed in related experimental E. coli mastitis challenge utilizing strain P4 (Blum 







Figure 4.3: Least square means and standard errors for A) dry matter intake (DMI), kg/d, and B) milk 
production, kg/d, from cows with an infected rear quarter following inoculation (d 0; ~800 CFU 
Escherichia coli P4). Treatment was implemented 24 h post inoculation with one of three treatments 
for 4 consecutive days: 125 mg ceftiofur hydrochloride daily (AB), sterile saline twice daily (CON), or 
















TRT P = 0.37
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Clinical characteristics of infected cows tended to vary for heart rate across 
treatment (P = 0.09; Table 4.3; Appendix 1). Heart rate (beats/minute) for AB treated 
cows was slower than the rate for cows receiving CON treatment. Biologically 
speaking, the difference in heart rate between AB and CON treatments is negligible; 
however, increases in heart rate are positively correlated with severity of the 
intramammary infection when cows are experimentally challenged with E. coli 
(Lohuis et al., 1990). Fever (i.e., rectal temperature > 39.4°C) is typically observed 
within the first 24 hours of cows challenged with E. coli mastitis (Bannerman et al., 
2004). Blum and associates (2017) observed similar results to the current study as 
cows challenged with strain P4 did not have elevated rectal temperatures or fever 
following inoculation (Appendix 2). Respiration rate did not vary across treatment or 






Table 4.3: Clinical characteristics among treatment groups following inoculation through day 35 
post inoculation. Cows were infected with ~800 CFU of Escherichia coli P4 into one rear mammary 
quarter and treated 24 h later for 4 consecutive days. 
 Treatment1  P-value 





70.3b 73.7a 71.8ab 1.0 0.09 0.23 
Respiration Rate, 
breaths/minute 
47.9 53.3 49.6 2.3 0.27 0.43 
Rectal 
Temperature, °C 
38.4 38.4 38.4 0.7 0.69 0.82 
a-bMeans within a row with different superscripts differ (P < 0.05). 
1Treatments: AB = 125 mg ceftiofur hydrochloride, 1×/day; CON = sterile, endotoxin-free buffered 







Mastitis cure has been defined many ways over the years and a variety of 
parameters and measurements can be taken into consideration. The National Mastitis 
Council (2004) defines healthy as milk samples that have SCC < 200,000 cells/mL, 
test negative for cultureable, pathogenic bacteria and have normal milk and udder 
(clinical score = 0). Days to reach these parameters following inoculation did not vary 
by treatment. Again, AB treatment was numerically lower than CON and OO and OO 
was similar to CON treatment (Table 4.4). Another common cure parameter for 
comparing antimicrobial therapy effectiveness assesses infected quarter 
bacteriological status post inoculation. An inoculated quarter is typically considered 
cured when at least two subsequent samples test negative for the inoculated bacterium 
at the end of the milk sampling period, typically 14-35 d post inoculation (Oldham 
and Daley, 1991; Shpigel et al., 1997). Re-occurrence of infection during this period 
is typically considered to be caused by the bacterium from the initial inoculation 
(National Mastitis Council, 2004). In the current study, no differences between 







Table 4.4: Number of days post inoculation to reach cure parameters for two consecutive samples. 
Cows were infected with ~800 CFU of Escherichia coli P4 into one rear mammary quarter and 
treated 24 h later for 4 consecutive days. 
 Treatment1   
 AB CON OO SEM P-value TRT 
SCC < 200,000 
cells/mL2 
21.0 22.8 21.0 4.9 0.92 
logCFU = 0 3 3.3 4.4 5.5 1.1 0.38 
Clinical Score = 0 8.8 12.8 12.8 2.7 0.50 
1Treatments: AB = 125 mg ceftiofur hydrochloride, 1×/day; CON = sterile, endotoxin-free buffered 
solution, 2×/day; OO = 8,930 μg citral (1% vol/vol), 2×/day 
2Infected quarter somatic cell count 








In conclusion, citral did not differ from antibiotic treatment or sterile, buffered 
solution. Although citral exhibits low MIC and MBC in vitro and effective 
antimicrobial activity against E. coli in milk, it was ineffective as a therapy to cure 
experimentally-induced E. coli mastitis. Citral exhibited some anti-inflammatory 
effects in the udder through reduced SCC in milk. However, reduced SCC during E. 
coli mastitis may not be desirable. The antimicrobial and anti-inflammatory effects of 
citral may be better suited for use as a topical disinfectant within the dairy industry. 
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Summary and Conclusion 
 
This dissertation explored the possible use of PlyC and citrus oils as 
alternatives to antibiotic therapies for bovine mastitis. Varying doses of PlyC are non-
toxic and do not alter ROS production in bovine neutrophils. The use of PlyC as an 
alternative therapy for Strep. uberis mastitis is promising where PlyC may not 
interfere with immune response during mastitis as neutrophils are the primary cell 
initially recruited during the onset of mastitis. Citrus oils demonstrated as equally 
promising results. The essential oil and its components were dissolved in ethanol to 
maintain the oils in solution. Previously, similar research had been conducted with the 
oils dissolved in the industrial solvent, DMSO; however, use of DMSO is forbidden 
in the U.S. dairy industry. Components of citrus oils, citral and linalool, demonstrated 
greater antimicrobial activity against isolated, environmental bovine mastitis 
pathogen E. coli strain P4 than the essential oil in both broth and bovine milk for 
planktonic growth and established biofilm eradication. In addition, citral and linalool 
will likely not interfere with the immune response of the mammary gland during 
mastitis as both did not inhibit neutrophil oxidative burst response and were 
negligibly toxic. The concentrations required to maintain the oils in solution were 
also tested and did not impact the antimicrobial or immune results.  
 Citral looked the most promising of the components of citrus oils as it 
required lower doses to induce antimicrobial effects and demonstrated equal effects 
toward bovine neutrophils as the other active component, linalool. It was prudent to 
test the effectiveness of citral against E. coli in an experimentally-induced, mastitis 





hydrochloride), or control (sterile, endotoxin-free buffered solution). Citral did 
demonstrate some anti-inflammatory effects through reduced SCC during the 
treatment period; however, effects were transient and unlikely to benefit as a 
therapeutic for E. coli bovine mastitis. 
 In conclusion, lysin PlyC is a promising alternative to antibiotics for treatment 
and management of bovine mastitis caused by streptococcal species. The future 
directions for PlyC will likely involve testing the curative effects of PlyC against 
experimentally-induced bovine mastitis. On the other hand, citrus oils and specifically 
citral appear to have greater antimicrobial effects against bacteria in vitro and in the 











Appendix 1: Least square means and standard errors for heart rate (beats/minute) from cows with an 
infected rear quarter following inoculation (d 0; ~800 CFU Escherichia coli P4). Treatment was 
implemented 24 h post inoculation with one of three treatments for 4 consecutive days: 125 mg 
ceftiofur hydrochloride daily (AB), sterile saline twice daily (CON), or 8,930 μg citral (1% vol/vol) 























Day, relative to inoculation
AB CON OO
TRT P = 0.09
TRT x Day P = 0.23






Appendix 2: Least square means and standard errors for respiration rate (breaths/minute) from cows 
with an infected rear quarter following inoculation (d 0; ~800 CFU Escherichia coli P4). Treatment 
was implemented 24 h post inoculation with one of three treatments for 4 consecutive days: 125 mg 
ceftiofur hydrochloride daily (AB), sterile saline twice daily (CON), or 8,930 μg citral (1% vol/vol) 
































Day, relative to inoculation
AB CON OO
TRT P = 0.28
TRT x Day P = 0.43






Appendix 3: Least square means and standard errors for rectal temperature (degrees Celsius) from 
cows with an infected rear quarter following inoculation (d 0; ~800 CFU Escherichia coli P4). 
Treatment was implemented 24 h post inoculation with one of three treatments for 4 consecutive days: 
125 mg ceftiofur hydrochloride daily (AB), sterile saline twice daily (CON), or 8,930 μg citral (1% 































Day, relative to inoculation
AB CON OO
TRT P = 0.69
TRT x Day P = 0.82
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